RxDoctor Payments Data

Barbara Stitt

Family · South Bend, INNPI 1790718476

Payments from drug & device makers

$1,778in general payments, 2019–2025

Across 72 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$415
  • GSK$355
  • Genentech USA, Inc.$313
  • Regeneron Healthcare Solutions, Inc.$238
  • Boston Scientific$112
  • Amgen$73
  • plus $273 from 8 others

What the payments were for

  • Food & beverage$1,72197%
  • Education$573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,778 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$81,674
Medicare patients
215
Services billed
2,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$92,704
Breo ElliptaFluticasone/Vilanterol91$46,934
Advair HfaFluticasone Propion/Salmeterol50$27,181
SymbicortBudesonide/Formoterol Fumarate41$18,862
Arnuity ElliptaFluticasone Furoate37$14,719
Fluticasone-SalmeterolFluticasone Propion/Salmeterol73$9,590
Fluticasone-VilanterolFluticasone/Vilanterol14$8,042
Fluticasone Propionate HfaFluticasone Propionate21$4,697
Epinephrine22$3,098
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$3,041
Wixela InhubFluticasone Propion/Salmeterol28$2,645
Albuterol Sulfate HfaAlbuterol Sulfate126$2,602
Hydroxyzine Hcl99$2,528
Azelastine Hcl88$2,342
Fluticasone Propionate108$1,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$355$154,358240 claims
AstraZenecaSymbicort$415$18,86241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →